OPKOPKO Health, Inc.
Price
+10.0%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growth steady, the market undecided.
We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA® (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for further development and commercialization of Somatrogon (hGH-CTP).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
OPKO Health, Inc. (OPK) reported revenue of $164M in Q2 2026 (quarter ended Jun 30, 2026), up 4.3% from the same quarter a year earlier. That came with a gross margin of 49% and net loss of $8.4M. For the full year FY2025, revenue was $607M (−15% year on year) and net income −$226M. Its largest product in Q2 2026 was Service at $75M, 40% of the disclosed total, ahead of Intellectual Property And Other at 25%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 15, 2026On October 14, 2026, OPKO Health, Inc., a Delaware corporation (“OPKO”), its wholly owned subsidiary, BioReference Health, LLC (“BioReference” and together with OPKO, “Seller”), and Laboratory Corporation of America Holdings, a Delaware corporation (“Buyer”), entered into an Asset Purchase Agreement (the “Purchase …Material agreement entered · Form 8-K
- Oct 2, 2026On October 1, 2026, OPKO Health, Inc. (the “Company”) determined that its 3.75% Convertible Senior Notes due 2029 (the “Notes”), of which approximately $121 million is outstanding, are convertible by holders of such Notes through December 31, 2026.Other event · Form 8-K
- Aug 14, 2026On August 13, 2026, OPKO Health, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024 (the “Original Agreement”; and as amended by the Amendment, the “Amended Agreement”) with certain purchasers party thereto from time to time, its wholly-owned …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $187.4MThe company’s own SEC segment disclosure.
- Service$74.5M40%
- Intellectual Property And Other$46.1M25%
- Transfer Of Intellectual Property And Other$46.1M25%
- Rayaldee$14.3M8%
- Royalty$6.4M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #18 of 21 by RyuScore